Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants.
Han K, Gevorkyan H, Sadik Shaik J, Crauwels H, Leemereise C, Bontempo G, Win B, Chounta V, Seal C, DeMoor R, D'Amico R, Spreen WR, Ford SL. Han K, et al. Among authors: bontempo g. Antimicrob Agents Chemother. 2024 Jan 10;68(1):e0078123. doi: 10.1128/aac.00781-23. Epub 2023 Dec 1. Antimicrob Agents Chemother. 2024. PMID: 38038460 Free PMC article.
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies.
Walmsley S, Smith DE, Górgolas M, Cahn PE, Lutz T, Lacombe K, Kumar PN, Wynne B, Grove R, Bontempo G, Moodley R, Okoli C, Kisare M, Jones B, Clark A, Ait-Khaled M. Walmsley S, et al. Among authors: bontempo g. AIDS Res Ther. 2024 Mar 21;21(1):17. doi: 10.1186/s12981-024-00604-9. AIDS Res Ther. 2024. PMID: 38515183 Free PMC article.
Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical Settings.
Jonsson-Oldenbüttel C, Ghosn J, van der Valk M, Florence E, Vera F, De Wit S, Rami A, Bonnet F, Hocqueloux L, Hove K, Ait-Khaled M, DeMoor R, Bontempo G, Latham CL, Gutner CA, Iyer S, Gill M, Czarnogorski M, D'Amico R, van Wyk J. Jonsson-Oldenbüttel C, et al. Among authors: bontempo g. J Acquir Immune Defic Syndr. 2024 Aug 15;96(5):472-480. doi: 10.1097/QAI.0000000000003448. Epub 2024 Jul 9. J Acquir Immune Defic Syndr. 2024. PMID: 38985445 Free PMC article. Clinical Trial.
Implementation of long-acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations.
Gutner CA, Hocqueloux L, Jonsson-Oldenbüttel C, Vandekerckhove L, van Welzen BJ, Slama L, Crusells-Canales M, Sierra JO, DeMoor R, Scherzer J, Ait-Khaled M, Bontempo G, Gill M, Patel N, D'Amico R, Hove K, Baugh B, Barnes N, Hadi M, Low EL, Anand SB, Hamilton A, Garges HP, Czarnogorski M. Gutner CA, et al. Among authors: bontempo g. J Int AIDS Soc. 2024 Jul;27(7):e26243. doi: 10.1002/jia2.26243. J Int AIDS Soc. 2024. PMID: 38978405 Free PMC article. Clinical Trial.
COVID-19-induced neuropsychiatric symptoms can persist long after acute infection: a 2-year prospective study of biobehavioral risk factors and psychometric outcomes.
Colizzi M, Comacchio C, De Martino M, Peghin M, Bontempo G, Chiappinotto S, Fonda F, Isola M, Tascini C, Balestrieri M, Palese A. Colizzi M, et al. Among authors: bontempo g. Ir J Psychol Med. 2024 Feb 14:1-8. doi: 10.1017/ipm.2023.53. Online ahead of print. Ir J Psychol Med. 2024. PMID: 38351842
32 results